Literature DB >> 12410907

Use of artificial networks in clinical trials: a pilot study to predict responsiveness to donepezil in Alzheimer's disease.

Patrizia Mecocci1, Enzo Grossi, Massimo Buscema, Marco Intraligi, Rita Savarè, Patrizia Rinaldi, Antonio Cherubini, Umberto Senin.   

Abstract

OBJECTIVES: To evaluate the accuracy of artificial neural networks compared with discriminant analysis in classifying positive and negative response to the cholinesterase inhibitor donepezil in a group of Alzheimer's disease (AD) patients.
DESIGN: Convenience sample.
SETTING: Patients with mild to moderate AD consecutively admitted to a geriatric day hospital and treated with donepezil 5 mg/day. PARTICIPANTS: Sixty-one older patients of both sexes with AD. MEASUREMENTS: Accuracy in detecting subjects sensitive (responders) or not (nonresponders) to 3-month therapy with ANNs. The criterion standard for evaluation of efficacy was the scores of Alzheimer's Disease Assessment Scale-Cognitive portion and Clinician's Interview Based Impression of Change-plus scales.
RESULTS: ANNs were more effective in discriminating between responders and nonresponders than other advanced statistical methods, particularly linear discriminant analysis. The total accuracy in predicting the outcome was 92.59%.
CONCLUSIONS: ANNs appear to be a useful tool in detecting patient responsiveness to pharmacological treatment in AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410907     DOI: 10.1046/j.1532-5415.2002.50516.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  7 in total

1.  Artificial neural networks and artificial organisms can predict Alzheimer pathology in individual patients only on the basis of cognitive and functional status.

Authors:  Massimo Buscema; Enzo Grossi; David Snowdon; Piero Antuono; Marco Intraligi; Guido Maurelli; Rita Savarè
Journal:  Neuroinformatics       Date:  2004

2.  Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review.

Authors:  Federico Emanuele Pozzi; Elisa Conti; Ildebrando Appollonio; Carlo Ferrarese; Lucio Tremolizzo
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

3.  A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer's Disease.

Authors:  Ping-Huang Tsai; Shih-Chieh Chang; Fang-Chun Liu; Jenho Tsao; Yung-Hung Wang; Men-Tzung Lo
Journal:  Comput Math Methods Med       Date:  2015-05-18       Impact factor: 2.238

4.  Outcome predictors in autism spectrum disorders preschoolers undergoing treatment as usual: insights from an observational study using artificial neural networks.

Authors:  Antonio Narzisi; Filippo Muratori; Massimo Buscema; Sara Calderoni; Enzo Grossi
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-30       Impact factor: 2.570

5.  Development of machine learning models to predict RT-PCR results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with influenza-like symptoms using only basic clinical data.

Authors:  Thomas Langer; Martina Favarato; Riccardo Giudici; Gabriele Bassi; Roberta Garberi; Fabiana Villa; Hedwige Gay; Anna Zeduri; Sara Bragagnolo; Alberto Molteni; Andrea Beretta; Matteo Corradin; Mauro Moreno; Chiara Vismara; Carlo Federico Perno; Massimo Buscema; Enzo Grossi; Roberto Fumagalli
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2020-12-01       Impact factor: 2.953

6.  Placental determinants of fetal growth: identification of key factors in the insulin-like growth factor and cytokine systems using artificial neural networks.

Authors:  Maria E Street; Enzo Grossi; Cecilia Volta; Elena Faleschini; Sergio Bernasconi
Journal:  BMC Pediatr       Date:  2008-06-17       Impact factor: 2.125

7.  Application of gene expression programming and neural networks to predict adverse events of radical hysterectomy in cervical cancer patients.

Authors:  Maciej Kusy; Bogdan Obrzut; Jacek Kluska
Journal:  Med Biol Eng Comput       Date:  2013-10-18       Impact factor: 2.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.